What is the primary intervention for Thrombotic Thrombocytopenic Purpura (TTP)?

What is the primary intervention for Thrombotic Thrombocytopenic Purpura (TTP)?

• A. Plasmapheresis to remove plasma and replace it with fresh frozen plasma.
• B. Platelet transfusion as first line.
• C. High-dose anticoagulation with heparin.
• D. Broad-spectrum antibiotics.

Answer: (A)

Thrombotic Thrombocytopenic Purpura is driven by a severe deficiency of the enzyme ADAMTS13, which normally cleaves ultra-large von Willebrand factor multimers. Without ADAMTS13, these ULVWF multimers promote widespread platelet aggregation in small vessels, causing microangiopathic hemolytic anemia and low platelets. The primary treatment is plasmapheresis (therapeutic plasma exchange), which rapidly removes the autoantibodies against ADAMTS13 and replaces the deficient enzyme with normal plasma. This directly tackles the underlying cause, decreases ongoing formation of microthrombi, and improves survival. Platelet transfusion isn’t given first because adding platelets can feed the existing microthrombi and worsen the condition unless there is life-threatening bleeding. Heparin anticoagulation isn’t effective here, since the problem isn’t a fibrin-platelet clot driven by the coagulation cascade but an antibody-mediated deficiency of ADAMTS13. Broad-spectrum antibiotics don’t address the autoimmune microangiopathy at all.

Thrombotic Thrombocytopenic Purpura is driven by a severe deficiency of the enzyme ADAMTS13, which normally cleaves ultra-large von Willebrand factor multimers. Without ADAMTS13, these ULVWF multimers promote widespread platelet aggregation in small vessels, causing microangiopathic hemolytic anemia and low platelets. The primary treatment is plasmapheresis (therapeutic plasma exchange), which rapidly removes the autoantibodies against ADAMTS13 and replaces the deficient enzyme with normal plasma. This directly tackles the underlying cause, decreases ongoing formation of microthrombi, and improves survival.

Platelet transfusion isn’t given first because adding platelets can feed the existing microthrombi and worsen the condition unless there is life-threatening bleeding. Heparin anticoagulation isn’t effective here, since the problem isn’t a fibrin-platelet clot driven by the coagulation cascade but an antibody-mediated deficiency of ADAMTS13. Broad-spectrum antibiotics don’t address the autoimmune microangiopathy at all.